Approach to High-Risk Multiple Myeloma.

Improving the outcome of high-risk myeloma (HRMM) is a key therapeutic aim for the next decade. To achieve this aim, it is necessary to understand in detail the genetic drivers underlying this clinical behavior and to target its biology therapeutically. Advances have already been made, with a focus on consensus guidance and the application of novel immunotherapeutic approaches. Cases of HRMM are likely to have impaired prognosis even with novel strategies. However, if disease eradication and minimal disease states are achieved, then cure may be possible.

• Publication year

  2024

• Venue

  Hematology/Oncology Clinics of North America

• Publication date

  2024-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.hoc.2023.12.008PMID 38195306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients

  2023cited by this paper
• Multiomic mapping of acquired chromosome 1 copy number and structural variants to identify therapeutic vulnerabilities in multiple myeloma.

  2023cited by this paper
• The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.

  2023cited by this paper
• IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical Impact.

  2023cited by this paper
• Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

  2022cited by this paper
• Optimizing the value of lenalidomide maintenance by genetic profiling - an analysis of 556 Myeloma XI trial patients.

  2022cited by this paper
• Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level

  2022cited by this paper
• The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors

  2022cited by this paper
• Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma

  2022cited by this paper
• Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma

  2022cited by this paper
• Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer

  2021cited by this paper
• Extramedullary disease in multiple myeloma

  2021cited by this paper
• High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse

  2021cited by this paper
• The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape

  2021cited by this paper
• Chromothripsis as a pathogenic driver of multiple myeloma.

  2021cited by this paper
• Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

  2021cited by this paper
• Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

  2021cited by this paper
• MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

  2021cited by this paper
• Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

  2021cited by this paper
• Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

  2020cited by this paper
• Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials

  2020cited by this paper
• Revealing the impact of structural variants in multiple myeloma.

  2020cited by this paper
• Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

  2020cited by this paper
• Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN.

  2020cited by this paper
• Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma

  2020cited by this paper
• Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns

  2020cited by this paper
• Reconstructing the evolutionary history of multiple myeloma.

  2020cited by this paper
• Extramedullary Disease in Multiple Myeloma

  2020cited by this paper
• MYC dysregulation in the progression of multiple myeloma

  2019cited by this paper
• High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.

  2019cited by this paper
• Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma

  2019cited by this paper
• Timing the initiation of multiple myeloma

  2019cited by this paper
• Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

  2019cited by this paper
• Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

  2019cited by this paper
• Mutational processes contributing to the development of multiple myeloma

  2019cited by this paper
• Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

  2018cited by this paper
• Genomic landscape and chronological reconstruction of driver events in multiple myeloma

  2018cited by this paper
• An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome

  2018cited by this paper
• The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

  2018cited by this paper
• Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis.

  2018cited by this paper
• Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms

  2018cited by this paper
• MCL1 gene co‐expression module stratifies multiple myeloma and predicts response to proteasome inhibitor‐based therapy

  2018cited by this paper
• A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

  2018cited by this paper
• MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

  2018cited by this paper
• Subclonal TP53 copy number is associated with prognosis in multiple myeloma.

  2018cited by this paper
• High‐risk Multiple Myeloma: Definition and Management

  2017cited by this paper
• Evolutionary biology of high-risk multiple myeloma

  2017cited by this paper
• ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

  2017cited by this paper
• Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

  2017cited by this paper
• Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

  2017cited by this paper
• The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma

  2017cited by this paper
• Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

  2017cited by this paper
• The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

  2017cited by this paper
• Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

  2017cited by this paper
• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

  2016cited by this paper
• RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response

  2016cited by this paper
• Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

  2016cited by this paper
• Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

  2016cited by this paper
• Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma

  2015cited by this paper
• The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

  2015cited by this paper
• Inhibiting MEK in MAPK pathway-activated myeloma

  2015cited by this paper
• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

  2015cited by this paper
• Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.

  2014cited by this paper
• Current and potential epigenetic targets in multiple myeloma.

  2014cited by this paper
• IMWG consensus on risk stratification in multiple myeloma

  2014cited by this paper
• Jumping translocations and high-risk myeloma.

  2014cited by this paper
• Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

  2014cited by this paper
• Childhood B-acute lymphoblastic leukemia: a genetic update

  2014cited by this paper
• APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

  2014cited by this paper
• Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

  2014cited by this paper
• Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma

  2014cited by this paper
• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

  2014cited by this paper
• Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation

  2014cited by this paper
• Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.

  2014cited by this paper
• Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

  2014cited by this paper
• Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice

  2013cited by this paper
• Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Assessing response of myeloma bone disease with diffusion-weighted MRI.

  2012cited by this paper
• The genetic architecture of multiple myeloma

  2012cited by this paper
• Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

  2011cited by this paper
• Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

  2011cited by this paper
• Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.

  2011cited by this paper
• Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

  2011cited by this paper
• A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

  2010cited by this paper
• International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

  2009cited by this paper
• BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.

  2009cited by this paper
• A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

  2006cited by this paper
• Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

  2006cited by this paper
• International staging system for multiple myeloma.

  2005cited by this paper
• Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

  2005cited by this paper
• A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma

  2004cited by this paper
• Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

  2004cited by this paper
• Homing of antibody secreting cells

  2003cited by this paper
• Plasma-cell homing

  2003cited by this paper
• Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.

  2001cited by this paper
• Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

  2000cited by this paper
• p53 gene mutations in multiple myeloma.

  1997cited by this paper

• The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

  2024cites this paper